Cost Effectiveness of Lenalidomide in the Treatment of Transfusion-Dependent Myelodysplastic Syndromes in the United States

Cancer Control - United States
doi 10.1177/107327480601304s04
Full Text
Abstract

Available in full text

Date
Authors
Publisher

SAGE Publications

Related search

Impact of Lenalidomide Use Among Non-Transfusion Dependent Patients With Myelodysplastic Syndromes

American Journal of Hematology
Hematology
2018English

Cost-Effectiveness in Canada of Azacitidine for the Treatment of Higher-Risk Myelodysplastic Syndromes

Current Oncology
Oncology
2013English

Management of Cytopenias During Treatment With Lenalidomide in Patients With Myelodysplastic Syndromes

The Open Leukemia Journal
2010English

A Calcium- And Calpain-Dependent Pathway Determines the Response to Lenalidomide in Myelodysplastic Syndromes

Nature Medicine
BiochemistryMedicineGeneticsMolecular Biology
2016English

Practical Considerations in the Use of Lenalidomide Therapy for Myelodysplastic Syndromes

Cancer Control
MedicineOncologyHematology
2006English

Developments in the Treatment of Transfusion-Dependent Anemia in Patients With Myelodysplastic Syndromes: Epidemiology, Etiology, Genetics, and Targeted Therapies

Advances in Genomics and Genetics
2014English

Hematologic Responses to Deferasirox Therapy in Transfusion-Dependent Patients With Myelodysplastic Syndromes

Haematologica
Hematology
2012English

Lenalidomide: Targeted Anemia Therapy for Myelodysplastic Syndromes

Cancer Control
MedicineOncologyHematology
2006English

Cost-Effectiveness of Alemtuzumab in the Treatment of Relapsing Forms of Multiple Sclerosis in the United States

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy